
    
      Patients will be required to stay in our hospitals to receive the immunotherapy. Allogeneic
      peripheral blood mononuclear cells from healthy donors and the autologous peripheral
      mononuclear cells will alternately used for the treatment. Patients are expected to spend at
      least 6 to 12 months in the hospital and won't be released until they have improved
      significantly.
    
  